EXEL
Exelixis IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$12.61B
P/E Ratio
16.61
EPS
$3.02
Beta
0.39
52W High
$51.63
52W Low
$33.76
50-Day MA
$45.16
200-Day MA
$42.25
Dividend Yield
—
Profit Margin
35.10%
Forward P/E
15.72
PEG Ratio
2.27
About Exelixis Inc
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Fundamentals
| Revenue (TTM) | $2.38B |
| Gross Profit (TTM) | $2.29B |
| EBITDA | $985.84M |
| Operating Margin | 41.10% |
| Return on Equity | 41.00% |
| Return on Assets | 22.00% |
| Revenue/Share (TTM) | $8.91 |
| Book Value | $7.63 |
| Price-to-Book | 6.45 |
| Price-to-Sales (TTM) | 5.31 |
| EV/Revenue | 4.999 |
| EV/EBITDA | 12.05 |
| Quarterly Earnings Growth (YoY) | 43.60% |
| Quarterly Revenue Growth (YoY) | 10.00% |
| Shares Outstanding | $251.35M |
| Float | $204.56M |
| % Insiders | 1.81% |
| % Institutions | 107.53% |
Historical Volatility
HV 10-Day
33.10%
HV 20-Day
47.49%
HV 30-Day
45.52%
HV 60-Day
39.16%
HV Rank
64.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($49.65 target)
1
Strong Buy9
Buy9
Hold1
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026